RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Amplia Therapeutics Stock

Amplia Therapeutics Market capitalization 2024

Amplia Therapeutics Market capitalization

29.94 M AUD

Ticker

ATX.AX

ISIN

AU0000023822

WKN

A2N5RL

In 2024, Amplia Therapeutics's market cap stood at 29.94 M AUD, a 76.5% increase from the 16.96 M AUD market cap in the previous year.

The Amplia Therapeutics Market capitalization history

YEARMarket Capitalization (undefined AUD)
202429.94
202316.85
202217.93
202122.02
20207.34
20194.48
20187.71
201795.74
201680.98
201530.09
201422.58
201318.22
2012-

Amplia Therapeutics Aktienanalyse

What does Amplia Therapeutics do?

Amplia Therapeutics Ltd was originally founded in 2012 and is based in Sydney, Australia. The company focuses on the development of novel therapies for cancer and other serious diseases. Amplia's main focus is on the development of peptide-based therapeutics, which are polypeptides derived from naturally occurring proteins. The company also places special emphasis on non-coding RNA (ncRNA) research and is working on the discovery, development, and commercialization of drugs that specifically target ncRNA. Amplia already holds various patents and approvals in this field. Amplia's core business is the research and development of drugs for cancer. The company collaborates with academic research groups and institutions worldwide and works closely with manufacturers of synthetic peptides to ensure high quality and efficacy in drug production. Amplia has developed various drug platforms to support its research activities. One of these platforms is the peptide library, which contains a large collection of synthetic peptides that can be used against different types of cancer. Another platform is ncRNA-based therapeutics, which exert their effects by inhibiting ncRNA molecules. Currently, Amplia Therapeutics has several drugs in various stages of clinical development. One example is AMP945, a peptide designed as a potential medication for triple-negative breast cancer. The drug targets a protein receptor found on the surface of cancer cells and has shown promising results in inhibiting tumor growth in animal models. Another example is ATX101, an ncRNA inhibitor also being developed as a potential medication for cancer. The inhibitor targets a specific form of ncRNA molecule that is overproduced in various types of cancer. In animal models, the drug has shown promising results in preventing tumor progression. Overall, Amplia Therapeutics Ltd aims to develop drugs that can significantly improve the lives of patients. The company strives to set new standards in cancer therapy and continuously works to improve its technology platforms and expand its product pipeline. Amplia Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring Amplia Therapeutics's Market Capitalization

Amplia Therapeutics's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Amplia Therapeutics's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Amplia Therapeutics's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Amplia Therapeutics’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Amplia Therapeutics stock

What is the current Amplia Therapeutics market capitalization?

The current market capitalization of Amplia Therapeutics is 29.94 M AUD.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Amplia Therapeutics.

How has the market capitalization of Amplia Therapeutics developed in recent years?

The market capitalization of Amplia Therapeutics has increased/decreased by 76.5% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Amplia Therapeutics?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Amplia Therapeutics?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Amplia Therapeutics have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Amplia Therapeutics pay?

Over the past 12 months, Amplia Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Amplia Therapeutics is expected to pay a dividend of 0 AUD.

What is the dividend yield of Amplia Therapeutics?

The current dividend yield of Amplia Therapeutics is .

When does Amplia Therapeutics pay dividends?

Amplia Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Amplia Therapeutics?

Amplia Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Amplia Therapeutics?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Amplia Therapeutics located?

Amplia Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Amplia Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Amplia Therapeutics from 9/29/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Amplia Therapeutics pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Amplia Therapeutics in the year 2023?

In the year 2023, Amplia Therapeutics distributed 0 AUD as dividends.

In which currency does Amplia Therapeutics pay out the dividend?

The dividends of Amplia Therapeutics are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Amplia Therapeutics

Our stock analysis for Amplia Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Amplia Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.